{"id":"soludronate","safety":{"commonSideEffects":[{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Musculoskeletal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a bisphosphonate, soludronate localizes to sites of bone resorption and is internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway. This disruption prevents osteoclast function and survival, leading to reduced bone turnover and increased bone mineral density. The drug is designed to treat conditions characterized by excessive bone loss.","oneSentence":"Soludronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and disrupting the mevalonate pathway in osteoclasts.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:35:23.235Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis (phase 3 development)"}]},"trialDetails":[{"nctId":"NCT05602493","phase":"PHASE3","title":"A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xeolas Pharmaceuticals Limited","startDate":"2022-11-22","conditions":"Bone Loss, Alveolar","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Soludronate®","genericName":"Soludronate®","companyName":"Xeolas Pharmaceuticals Limited","companyId":"xeolas-pharmaceuticals-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Soludronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and disrupting the mevalonate pathway in osteoclasts. Used for Osteoporosis (phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}